Precision medicine strategies, such as GLP-1 receptor agonists for obesity-related HFpEF or AF ablation, highlight phenotype-specific therapeutic potential.<h4>Conclusion</h4>HFpEF probability scores are valuable tools but must be interpreted in the context of individual phenotypes. This evidence concerns the gene GLP1R and atrial fibrillation.